leisure time -WSS

leisure time

author：explore 2025-10-01 22:48:57 - browse：6

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Cancer drug shortages' outsize impact on ovarian cancer patients

WSS

Transgender sports debate: Physicians say bans are health issue

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Neurocrine congenital adrenal hyperplasia trial succeeds

Patient advocates sound warning on FDA proposal on salt intake

Baltimore teen accused of firing into crowd during block party mass shooting

Listen: Racing for gene therapy & a pioneering approval

Wikipedia

leisure time

Wikipedia

DIEP, the 'gold standard' of breast reconstruction, is under threat

Hilary expected to bring catastrophic, life

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Cancer drug shortages' outsize impact on ovarian cancer patients

In Memoriam: Notable people who died in 2023

Listen: Racing for gene therapy & a pioneering approval

Apple is now the first public company to be valued at $3 trillion

Clinical trials must include more disabled people

Virginia high school admissions case could be legal follow

Eli Lilly CEO gives to Mike Pence presidential super PAC

knowledge

Patient advocates sound warning on FDA proposal on salt intake

'A game

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

Living with Hashimoto's and celiac disease, and med school, too

FDA panel to weigh safety of artificial wombs for preterm births

New details revealed about Purdue's marketing of OxyContin

hotspot

focus

knowledge

hotspot